Media Articles Related to Maxalt-Mlt (Rizatriptan)
Research on an fMRI-Based Neurologic Signature of Physical Pain to be Presented at Upcoming 10th Annual Pain & Migraine Therapeutics Summit
Source: Conferences News From Medical News Today [2016.08.16]
As persistent pain is solely measured by self-report, research is currently being conducted to find objective methods of identifying physical pain in the brain.
10th Annual Pain & Migraine Therapeutics Summit, October 19-20, 2016, Chicago
Source: Conferences News From Medical News Today [2016.08.01]
Centrexion Therapeutics has announced a collaborative agreement with BioXcel to develop and commercialize innovative chronic pain therapeutics.
Migraine: Discovery of new genetic risk variants supports a vascular cause
Source: Headache / Migraine News From Medical News Today [2016.06.25]
Researchers have identified 28 new genetic risk variants for migraine, many of which are located in or near genes related to vascular disease.
Many with migraines have vitamin deficiencies, says study
Source: Headache / Migraine News From Medical News Today [2016.06.13]
A high percentage of children, teens and young adults with migraines appear to have mild deficiencies in vitamin D, riboflavin and coenzyme Q10 - a vitamin-like substance found in every cell of the...
Headache: Surprising Headache and Migraine Triggers
Source: MedicineNet Brain Tumor Specialty [2016.06.10]
Title: Headache: Surprising Headache and Migraine Triggers
Created: 5/18/2009 12:00:00 AM
Last Editorial Review: 6/10/2016 12:00:00 AM
Published Studies Related to Maxalt-Mlt (Rizatriptan)
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]
OBJECTIVE: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. BACKGROUND: Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100 mg non-responders will respond to other triptans... CONCLUSION: Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.
A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2011.04]
The objective of this study was to assess patient satisfaction with acute treatment of migraine with frovatriptan or rizatriptan by preference questionnaire. 148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1-3 attacks...
Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011.02]
A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo...
Efficacy of frovatriptan in the acute treatment of menstrually related migraine:
analysis of a double-blind, randomized, cross-over, multicenter, Italian,
comparative study versus rizatriptan. 
The objectives of this study are to assess the efficacy and safety of
frovatriptan, and rizatriptan in the subgroup of women with menstrually related
migraine of a multicenter, randomized, double blind, cross-over study. Each
patient received frovatriptan 2.5 mg or rizatriptan 10 mg in a randomized
sequence: after treating 3 episodes of migraine in not more than 3 months with
the first treatment, the patient had to switch to the other treatment...
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. [2009.08.06]
CONCLUSIONS: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.
Clinical Trials Related to Maxalt-Mlt (Rizatriptan)
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1) [Completed]
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed
drug in pediatric subjects with migraines.
After completion of a portion of the study (Panels A and B), a regulatory agency issued an
amended request that the 12-17 year old age group studied should include a similar number of
male and female subjects. Therefore, the study was amended to add an additional panel of
subjects (Panel C) to ensure gender balance specifically in this age group.
Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops [Withdrawn]
Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) [Completed]
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) [Completed]
A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine
attacks and duration of relief provided. This study will also provide additional efficacy
data on rizatriptan 5 mg and 10 mg for the treatment of migraine.
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) [Completed]
Reports of Suspected Maxalt-Mlt (Rizatriptan) Side Effects
Drug Ineffective (3),
Intestinal Ischaemia (2),
Abdominal Pain (1),
Cardiac Tamponade (1),
Sudden Death (1),
Abortion Spontaneous (1),
Drug Label Confusion (1), more >>